Author:
AlAli Alaa,Bushehri Ahmad,Park Jonathan C.,Krema Hatem,Lam Wai-Ching
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Ophthalmology,General Medicine
Reference9 articles.
1. MEK12 inhibitors in the treatment of gynecologic malignancies.;Miller;Gynecol Oncol,2014
2. . First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens R) in patients (pts) with advanced solid tumors.;Delord;J Clin Oncol,2010
3. . Safety and evidence of activity of MSC1936369, an oral MEK12 inhibitor, in patients with advanced malignancies.;Houede;J Clin Oncol,2011
4. . Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metatatic cancer.;McCannel;JAMA,2014
5. . Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small cell lung, breast, colon, and pan- creatic cancer.;Rinehart;J Clin Oncol,2004
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献